Provided by Tiger Fintech (Singapore) Pte. Ltd.

Pfizer

26.73
+0.49001.87%
Post-market: 26.67-0.0600-0.22%19:59 EST
Volume:54.34M
Turnover:1.45B
Market Cap:151.49B
PE:18.93
High:26.89
Open:26.40
Low:26.18
Close:26.24
Loading ...

U.S. FDA Approves Pfizer’s Adcetris® Combination Regimen for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

THOMSON REUTERS
·
13 Feb

FDA Approves Brentuximab Vedotin With Lenalidomide and Rituximab for Relapsed or Refractory Large B-Cell Lymphoma

THOMSON REUTERS
·
12 Feb

Earnings To Watch: Zoetis (ZTS) Reports Q4 Results Tomorrow

StockStory
·
12 Feb

Organon (OGN) Q4 Earnings Report Preview: What To Look For

StockStory
·
12 Feb

Q4 2024 Arvinas Inc Earnings Call

Thomson Reuters StreetEvents
·
12 Feb

Pfizer Inc. Stock Underperforms Tuesday When Compared To Competitors

Dow Jones
·
12 Feb

Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo

Benzinga
·
12 Feb

Jefferies Adjusts Price Target on Pfizer to $34 From $33

MT Newswires Live
·
11 Feb

Pfizer : Jefferies Raises Target Price to $34 From $33

THOMSON REUTERS
·
11 Feb

BRIEF-Alloy Therapeutics Establishes Multi-Year Collaboration With Pfizer

Reuters
·
11 Feb

Alloy Therapeutics: Under Terms of Collaboration, Alloy Will Receive an Upfront Payment From Pfizer

THOMSON REUTERS
·
11 Feb

Alloy Therapeutics: Will Be Eligible for Pre-Specified Preclinical to Commercial Milestones on Products Originating From Newly Developed Platform

THOMSON REUTERS
·
11 Feb

Arvinas announces anticipated upcoming milestones

TIPRANKS
·
11 Feb

Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

GlobeNewswire
·
11 Feb

Redburn Atlantic Adjusts Price Target on Pfizer to $29 From $27, Keeps Neutral Rating

MT Newswires Live
·
11 Feb

Pfizer, Astellas Cite 'Durable Benefit' in More Trial Results of Padcev Plus Keytruda in Urothelial Cancer

MT Newswires Live
·
11 Feb